Pulmonary pharmacology & therapeutics最新文献

{"title":"Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study","authors":"Tomasz Dębowski ,&nbsp;Monika Marko ,&nbsp;Barbara Rogala ,&nbsp;Paweł Majak ,&nbsp;Rafał Pawliczak","doi":"10.1016/j.pupt.2023.102272","DOIUrl":"10.1016/j.pupt.2023.102272","url":null,"abstract":"<div><h3>Introduction</h3><p>Extrafine formulation of beclomethasone/formoterol fixed combination (BDP/F pMDI HFA) is approved for both fixed maintenance and maintenance and reliever therapy (MART) of asthma, and recent data has proven that BDP/F pMDI HFA maintenance and reliever therapy is an effective alternative to other regimens.</p></div><div><h3>Objective</h3><p>This study aimed to assess the level of asthma control in a real-life setting in adult patients using extrafine BDP/F pMDI HFA fixed combination in a pressurized metered-dose inhaler (pMDI) as fixed maintenance dosing as well as maintenance and maintenance and reliever therapy. Additionally, we examined patients’ satisfaction with the inhaler device and compliance with therapy as essential factors determining asthma control.</p></div><div><h3>Methods</h3><p>This multicenter prospective non-interventional observational study lasted 4 months with 3 patient visits. We used the Asthma Control Questionnaire 7 (ACQ-7) to evaluate the degree of asthma control and Morisky Medication Adherence Scale (MMAS-4) to assess compliance. A self-developed questionnaire was used to assess satisfaction with the inhaler device.</p></div><div><h3>Results</h3><p>2179 patients using BDP/F pMDI HFA fixed combination as maintenance and reliever therapy or BDP/F pMDI HFA as maintenance therapy and SABA (short-acting beta₂-agonist) as a reliever for at least 2 months were included. During the prospective follow-up, we observed an upward trend in the FEV1% (forced expiratory volume in 1 s) predicted values, improvement in the control of symptoms as indicated by a decline in the mean ACQ-7 score was noted (1.62 at Visit 1 vs. 1.21 at Visit 2 vs. 0.94 at Visit 3, p &lt; 0.001) and increase in patients’ compliance (the number of patients that reported forgetting at times to take their medication was reduced from 49.7 % to 27.1 %, p &lt; 0.001). At the same time, we noted a reduction in the number of as-needed doses used for symptom relief (p &lt; 0.001). Most patients were satisfied with the pMDI, considered it easy and convenient to use, and preferred it to a dry powder inhaler (p &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>The use of extrafine BDP/F pMDI HFA as maintenance as well as reliever therapy seems to be associated with increased asthma control and better compliance to therapy.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102272"},"PeriodicalIF":3.2,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1094553923000846/pdfft?md5=8a220b559f944d45e1562736287df2a3&pid=1-s2.0-S1094553923000846-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients","authors":"Lily Zheng ,&nbsp;Mohammad H. Alshaer ,&nbsp;Charles Peloquin ,&nbsp;Veena Venugopalan ,&nbsp;Hassan M. Alnuaimat ,&nbsp;Maureen Converse","doi":"10.1016/j.pupt.2023.102271","DOIUrl":"10.1016/j.pupt.2023.102271","url":null,"abstract":"<div><h3>Background</h3><p>The impact of extracorporeal membrane oxygenation<span><span> (ECMO) on the pharmacokinetics/dynamics (PK/PD) of beta-lactam antibiotics have not been well studied in general, but cefepime specifically has the least amount of data. We aimed to investigate whether ECMO alters the PK of cefepime in adult </span>intensive care unit (ICU) patients.</span></p></div><div><h3>Methods</h3><p>This single-center, retrospective case-control study evaluated cefepime therapeutic drug<span><span><span> monitoring (TDM) results from ECMO patients that were matched 1:1 with TDM results in non-ECMO patients for drug regimen and renal function. The primary outcome was the difference in PK/PD of cefepime in ECMO compared with non-ECMO ICU patients. Secondary outcomes included hospital length of stay, treatment failure, </span>superinfection, </span>bacterial resistance, and survival to discharge.</span></p></div><div><h3>Results</h3><p><span>Eighty-two patients were included with 44 matched cefepime concentrations in each group. ECMO patients had higher free maximum concentrations (fCmax) (p = 0.003), lower free minimum concentration (fCmin)/1x minimum inhibitory concentration (MIC) ratios (</span><em>p</em> = 0.040), and lower attainment of free Cmin/4x MIC (<em>p</em><span> = 0.010). There were no differences between the groups for free Cmin, time above 1xMIC or 4x MIC, and pharmacokinetic parameters (ke, half-life, and Vd). Of those who survived to discharge, hospital length of stay was longer in the ECMO group (</span><em>p</em> &lt; 0.001). Patients on ECMO were more likely to experience treatment failure (<em>p</em> = 0.036). The incidence of bacterial resistance, superinfection, or survival were similar among the groups.</p></div><div><h3>Conclusion</h3><p>These data suggest that more aggressive empiric dosing may be warranted in patients on ECMO. Therapeutic drug monitoring and future prospective studies would provide more evidence to guide decision making regarding dose adjustments.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"84 ","pages":"Article 102271"},"PeriodicalIF":3.2,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)","authors":"Audrey Joannes ,&nbsp;Tom Voisin ,&nbsp;Claudie Morzadec ,&nbsp;Alice Letellier ,&nbsp;Francisco Llamas Gutierrez ,&nbsp;Dan Cristian Chiforeanu ,&nbsp;Cécile Le Naoures ,&nbsp;Stéphanie Guillot ,&nbsp;Bertrand Richard De Latour ,&nbsp;Simon Rouze ,&nbsp;Madeleine Jaillet ,&nbsp;Bruno Crestani ,&nbsp;Lutz Wollin ,&nbsp;Stéphane Jouneau ,&nbsp;Laurent Vernhet","doi":"10.1016/j.pupt.2023.102267","DOIUrl":"10.1016/j.pupt.2023.102267","url":null,"abstract":"<div><p><span><span><span>The tyrosine kinase inhibitor </span>nintedanib has been recently approved for the treatment of </span>Interstitial Lung Diseases<span> (ILDs) that manifest a progressive fibrosis phenotype other than </span></span>Idiopathic pulmonary Fibrosis (IPF).</p><p><span>Nintedanib reduces the development of lung fibrosis in various animal models resembling features of PF-ILD and </span><em>in vitro</em><span><span>, it inhibits the fibrosing phenotype of human lung fibroblasts (HLFs) isolated from patients with IPF. To get insight on the cellular and molecular mechanisms that drive the clinical efficiency of nintedanib </span>in patients with non-IPF PF-ILD, we investigated its effects on the fibrosing functions of HLFs derived from patients with PF-hypersensitivity pneumonitis (PF-HP, n = 7), PF-sarcoidosis (n = 5) and pleuroparenchymal fibroelastosis (PPFE, n = 4).</span></p><p>HLFs were treated with nintedanib (10 nM-1 μM) and then stimulated with PDGF-BB (25–50 ng/ml) or TGF-β1 (1 ng/ml) for 24–72 h to assess proliferation and migration or differentiation.</p><p><span>At nanomolar concentrations, nintedanib reduced the levels of PDGF receptor and ERK1/2 phosphorylation, the proliferation and the migration of PF-HP, PF-sarcoidosis and PPFE HLFs stimulated with PDGF-BB. Moreover, nintedanib also attenuates the myofibroblastic differentiation driven by TGF-β1 but only when it is used at 1 μM. The </span>drug<span> reduced the phosphorylation of SMAD2/3 and decreased the induction of collagen, fibronectin and α-smooth muscle actin expression induced by TGF-β1.</span></p><p>In conclusion, our results demonstrate that nintedanib counteracts fundamental fibrosing functions of lung fibroblasts derived from patients with PF-HP, PF-sarcoidosis and PPFE, at concentrations previously reported to inhibit control and IPF HLFs. Such effects may contribute to its clinical benefit in patients suffering from these irreversible ILDs.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102267"},"PeriodicalIF":3.2,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136398962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyvaso DPI: Drug-device characteristics and patient clinical considerations","authors":"Colleen McEvoy ,&nbsp;Rahul Argula ,&nbsp;Sandeep Sahay ,&nbsp;Shelley Shapiro ,&nbsp;Christina Eagan ,&nbsp;Anthony J. Hickey ,&nbsp;Chad Smutney ,&nbsp;Chris Dillon ,&nbsp;Thomas Winkler ,&nbsp;Brittany N. Davis ,&nbsp;Meredith Broderick ,&nbsp;Charles Burger","doi":"10.1016/j.pupt.2023.102266","DOIUrl":"10.1016/j.pupt.2023.102266","url":null,"abstract":"<div><p>Tyvaso DPI is a drug-device combination therapy comprised of a small, portable, reusable, breath-powered, dry powder inhaler (DPI) for the delivery of treprostinil. It is approved for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Tyvaso DPI utilizes single-use prefilled cartridges to ensure proper dosing. Unlike nebulizer devices, administration of Tyvaso DPI is passive and does not require coordination with the device. The low-flow rate design results in targeted delivery to the peripheral lungs due to minimal drug loss from impaction in the oropharynx. The inert fumaryl diketopiperazine (FDKP) excipient forms microparticles that carry treprostinil into the airways, with a high fraction of the particles in the respirable range. In a clinical study in patients with pulmonary arterial hypertension, Tyvaso DPI had similar exposure and pharmacokinetics, low incidence of adverse events, and high patient satisfaction compared with nebulized treprostinil solution. Tyvaso DPI may be considered as a first prostacyclin agent or for those that do not tolerate other prostacyclin formulations, patients with pulmonary comorbidities, patients with mixed Group 1 and Group 3 pulmonary hypertension, or those that prefer an active lifestyle and need a portable, non-invasive treatment. Tyvaso DPI is a patient-preferred, maintenance-free, safe delivery option that may improve patient compliance and adherence.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102266"},"PeriodicalIF":3.2,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1094553923000780/pdfft?md5=a2533bc287439f9ecc193b026c7bf7fd&pid=1-s2.0-S1094553923000780-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The compound artemisinin-hydroxychloroquine ameliorates bleomycin-induced pulmonary fibrosis in rats by inhibiting TGF-β1/Smad2/3 signaling pathway","authors":"Zhaojia Wang ,&nbsp;Min Liu ,&nbsp;Ying Ai ,&nbsp;Shaoqin Zheng ,&nbsp;Yingyi Chen ,&nbsp;Hujun Du ,&nbsp;Shijia Yuan ,&nbsp;Xueying Guo ,&nbsp;Yueming Yuan ,&nbsp;Guoming Li ,&nbsp;Jianping Song ,&nbsp;Changsheng Deng","doi":"10.1016/j.pupt.2023.102268","DOIUrl":"10.1016/j.pupt.2023.102268","url":null,"abstract":"<div><p><span>Pulmonary fibrosis<span><span><span> (PF) is a lethal disease characterized by a progressive decline in lung function. Currently, lung transplantation remains the only available </span>treatment for PF. However, both </span>artemisinin<span><span> (ART) and hydroxychloroquine (HCQ) possess potential antifibrotic properties. This study aimed to investigate the effects and mechanisms of a compound known as Artemisinin-Hydroxychloroquine (AH) in treating PF, specifically by targeting the TGF-β1/Smad2/3 pathway. To do this, we utilized an animal model of PF induced by a single tracheal drip of </span>bleomycin<span><span><span> (BLM) in Sprague-Dawley (SD) rats. The PF animal models were administered various doses of AH, and the efficacy and safety of AH were evaluated through pulmonary function testing<span>, blood routine tests, serum biochemistry tests, organ index measurements, and pathological examinations. Additionally, Elisa, </span></span>western blotting, and qPCR techniques were employed to explore the potential molecular mechanisms of AH in treating PF. Our findings reveal that AH effectively and safely alleviate PF by inhibiting BLM-induced specific inflammation, reducing </span>extracellular matrix<span> (ECM) deposition, and interfering with the TGF-β1/Smad2/3 signaling pathway. Notably, the windfall for this study is that the inhibition of ECM may initiate self-healing in the BLM-induced PF animal model. In conclusion, AH shows promise as a potential therapeutic </span></span></span></span></span>drug<span> for PF, as it inhibits disease progression through the TGF-β1/Smad2/3 signaling pathway.</span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102268"},"PeriodicalIF":3.2,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease","authors":"Akram Tayanloo-Beik ,&nbsp;Shayesteh Kokabi Hamidpour ,&nbsp;Mohaddese chaharbor ,&nbsp;Mostafa Rezaei-Tavirani ,&nbsp;Rasta Arjmand ,&nbsp;Hossein Adibi ,&nbsp;Hamid Ojagh ,&nbsp;Bagher Larijani ,&nbsp;Babak Arjmand","doi":"10.1016/j.pupt.2023.102269","DOIUrl":"10.1016/j.pupt.2023.102269","url":null,"abstract":"<div><p><span>Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterized by its heterogeneous nature, progressive course, and significant impact on individuals' </span>quality of life<span>. It is a prevalent global health issue affecting a substantial number of individuals and can pose life-threatening complications if left unmanaged. The development and course of COPD can be influenced by a range of risk factors, including genetic predisposition<span> and environmental exposures. Nevertheless, as researchers adopt a more comprehensive and expansive viewpoint of therapeutic techniques, the associated obstacles become more apparent. Indeed, a definitive medication for COPD that reliably leads to symptom alleviation has not yet been discovered. Therefore, the limitations of conventional therapy methods prompted researchers to focus on the advancement of novel procedures, potentially leading to significant outcomes. In contemporary times, the field of regenerative medicine and cell therapy has presented unprecedented opportunities for the exploration of innovative treatments for COPD, owing to the distinctive attributes exhibited by stem cells. Hence, it is imperative to provide due consideration to preclinical investigations and notable characteristics of stem cells as they serve as a means to comprehensively comprehend the fundamental mechanisms of COPD and uncover novel therapeutic strategies with enhanced efficacy for patients.</span></span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102269"},"PeriodicalIF":3.2,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury","authors":"Hailing Zhang ,&nbsp;Jiehong Li ,&nbsp;Xilong Wang ,&nbsp;Kai Wang ,&nbsp;JianPeng Xie ,&nbsp;Guanjin Chen ,&nbsp;Yijian Li ,&nbsp;Kai Zhong ,&nbsp;Jiahui Li ,&nbsp;Xin Chen","doi":"10.1016/j.pupt.2023.102263","DOIUrl":"10.1016/j.pupt.2023.102263","url":null,"abstract":"<div><h3>Background</h3><p>Acute lung injury (ALI), along with the more severe condition--acute respiratory distress syndrome (ARDS), is a major cause of respiratory failure in critically ill patients with high morbidity and mortality. Inositol-requiring protein 1α (IRE1α)/X box protein-1 (XBP1) pathway was proved to regulate lipopolysaccharide (LPS)-induced lung injury and inflammation. Yet, its role on epithelial β-catenin in LPS-induced ALI remains to be elucidated.</p></div><div><h3>Methods</h3><p>LPS-induced models were generated in mice (5 mg/kg) and Beas-2B cells (200 μg/mL). Two selective antagonists of IRE1α (4μ8c and STF-083010) were respectively given to LPS-exposed mice and cultured cells.</p></div><div><h3>Results</h3><p>Up-regulated expression of endoplasmic reticulum (ER) stress markers immunoglobulin-binding protein (BIP) and spliced X box protein-1(XBP-1s) was detected after LPS<span> exposure. Besides, LPS also led to a down-regulated total β-catenin level in the lung and Beas-2B cells, with decreased membrane distribution as well as increased cytoplasmic and nuclear accumulation, paralleled by extensively up-regulated downstream targets of the Wnt/β-catenin signaling. Treatment with either 4μ8c or STF-083010 not only significantly attenuated LPS-induced lung injury and inflammation, but also recovered β-catenin expression in airway epithelia, preserving the adhesive function of β-catenin while blunting its signaling activity.</span></p></div><div><h3>Conclusion</h3><p>These results illustrated that IRE1α/XBP1 pathway promoted the activation of airway epithelial β-catenin signaling in LPS-induced ALI.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102263"},"PeriodicalIF":3.2,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71485359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency","authors":"Zhaoyang Li ,&nbsp;Mitali Gaurav ,&nbsp;Leman Yel","doi":"10.1016/j.pupt.2023.102265","DOIUrl":"10.1016/j.pupt.2023.102265","url":null,"abstract":"<div><h3>Introduction</h3><p>The recommended standard dose for α₁-proteinase inhibitor (A1PI) augmentation therapy is 60 mg/kg once-weekly (QW) intravenous (IV) infusions that aim to maintain systemic A1PI levels &gt;11 μM, the biochemical efficacy threshold, in patients with α₁-antitrypsin deficiency (AATD). However, this standard dose may not be optimal for all patients. Body weight–based dosing, alternative dosing regimens, and treatment interruption periods were evaluated using population pharmacokinetic (PopPK) modeling and simulations.</p></div><div><h3>Methods</h3><p>A nonlinear mixed-effects PopPK model with covariate effects was developed using data from 3 clinical studies investigating 60 mg/kg QW IV A1PI infusions in patients with AATD (n = 65) to evaluate A1PI pharmacokinetic (PK) characteristics. Model-based simulations were conducted for predefined body weight categories, alternative dosing regimens (60–180 mg/kg QW or once every 2 weeks [Q2W]), and treatment interruption periods ranging from 3 to 14 days.</p></div><div><h3>Results</h3><p>A1PI PK characteristics were well described by a 2-compartment turnover model with zero-order input and linear elimination. Body weight was a statistically significant determinant of variability in central volume of distribution. Model-based simulations suggested that patients with a higher body weight may attain the 11 μM threshold quicker than patients with a lower body weight and that QW dosing was better at maintaining A1PI levels &gt;11 μM, even when higher Q2W doses were administered. Missing a dose for as few as 3 days could result in A1PI levels &lt;11 μM.</p></div><div><h3>Discussion</h3><p>Findings suggest that doses higher than 60 mg/kg administered QW might be more clinically beneficial in some patients with AATD, and that body weight should be considered in dose optimization.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102265"},"PeriodicalIF":3.2,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71485360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication use in people with cystic fibrosis before and after modulator therapy","authors":"Louise Lord ,&nbsp;Mark Hew ,&nbsp;Miriam TY. Leung ,&nbsp;Jedidiah I. Morton ,&nbsp;Jenni Ilomaki","doi":"10.1016/j.pupt.2023.102264","DOIUrl":"https://doi.org/10.1016/j.pupt.2023.102264","url":null,"abstract":"<div><h3>Background</h3><p>Long-term changes in medication dispensings post cystic fibrosis transmembrane conductance regulator<span> (CFTR) modulator initiation have not been described. Our study aimed to investigate changes in medication use following the initiation of modulator therapy in people with cystic fibrosis (PwCF) in Australia.</span></p></div><div><h3>Methods</h3><p>Using a 10% sample of the Australian Pharmaceutical Benefits Scheme (PBS) data between 2013 and 2022, linear regression was used to analyse dispensings in PwCF who initiated any modulator (cases) and matched PwCF controls not dispensed a modulator. The difference in mean number of total monthly dispensings pre- and post-modulator initiation was analysed, with separate analyses by medication class.</p></div><div><h3>Results</h3><p>A total of 247 cases were matched 1:1 to controls (case and control median age 21 years (IQR: 13–32), 55.1% male). Immediately after modulator initiation, the mean number of dispensings was 0.9 higher in the modulator group, but then decreased to the level of controls after approximately 5 years. After 7.5 years, cases had decreased opioids compared to the pre-modulator period (β-coefficient: −0.00131, 95% CI: −0.00164, −0.00097) whilst controls did not (β: −0.00014, 95% CI: −0.00042, 0.00014). Over the same time period controls had an increase in psychotropics<span> (β: 0.00389, 95% CI:0.00295, 0.00484) whilst cases remained stable (β: −0.00014, 95% CI: −0.0006, 0.00031). Women's health medications increased in cases (β:0.00026, 95% CI:0.0001, 0.00042) but decreased in controls (β: 0.00044, 95% CI: 0.00063, −0.00025).</span></p></div><div><h3>Conclusions</h3><p>Modulator initiation in PwCF was associated with decreased dispensings of opioids and psychotropics, and increased dispensings of women's health medications, suggesting improved patient outcomes across multiple clinical domains.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102264"},"PeriodicalIF":3.2,"publicationDate":"2023-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91956640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SIRT3 activator ganoderic acid D regulates airway mucin MUC5AC expression via the NRF2/GPX4 pathway","authors":"Jiancheng Wang ,&nbsp;Jiayao Li ,&nbsp;Yingying He ,&nbsp;Xiaochun Huang ,&nbsp;Jianguo Feng ,&nbsp;Li Liu ,&nbsp;Yulin Liu ,&nbsp;Xian Jiang ,&nbsp;Jing Jia","doi":"10.1016/j.pupt.2023.102262","DOIUrl":"10.1016/j.pupt.2023.102262","url":null,"abstract":"<div><h3>Purpose</h3><p><span><span>The expression of MUC5AC, a highly prevalent </span>airway mucin, is regulated by stimulatory factors such as </span>oxidative stress<span><span>. Ganoderic acid D (GAD) activates mitochondrial deacetylase SIRT3. SIRT3 regulates mitochondrial function through deacetylation of </span>mitochondrial proteins, thereby playing a significant role in alleviating oxidative stress-related diseases. Therefore, this study aimed to investigate the mechanisms and rationale underlying the regulation of MUC5AC expression by GAD.</span></p></div><div><h3>Methods</h3><p><span>Human airway epithelial cells (NCI–H292) were exposed to pyocyanin (PCN) to establish an </span><em>in vitro</em><span> cell model of airway mucus hypersecretion. The expression of SIRT3, MUC5AC, and NRF2 pathway proteins in cells was assessed. Cellular mitochondrial morphology and oxidative stress markers were analyzed. C57BL/6 mice were induced with </span><span><em>Pseudomonas aeruginosa</em></span> (PA) to establish an <em>in vivo</em><span> mouse model of airway mucus hypersecretion. The expression of SIRT3 and MUC5AC in the airways was examined. In addition, the differential expression of target genes in the airway epithelial tissues of patients with chronic obstructive pulmonary disease (COPD) was analyzed using publicly available databases.</span></p></div><div><h3>Results</h3><p>The results revealed a significant upregulation of MUC5AC expression and a significant downregulation of SIRT3 expression in relation to airway mucus hypersecretion. GAD inhibited the overexpression of MUC5AC in PCN-induced NCI-H292 cells and PA-induced mouse airways by upregulating SIRT3. GAD activated the NRF2/GPX4 pathway and inhibited PCN-induced oxidative stress and mitochondrial morphological changes in NCI-H292 cells. However, ML385 inhibited the regulatory effects of GAD on MUC5AC expression.</p></div><div><h3>Conclusion</h3><p>The SIRT3 activator GAD downregulated MUC5AC expression, potentially through activation of the NRF2/GPX4 pathway. Accordingly, GAD may be a potential treatment approach for airway mucus hypersecretions.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102262"},"PeriodicalIF":3.2,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}